Riskpilot← Back to searchSign inGet full accessMedans Oy
OYActiveY-tunnus 2078491-4Puolikkotie 8Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2006— employees
Revenue 2025
EUR 1,5M
-8% vs 2024
EBITDA margin
7.9%
+85% vs 2024
Equity ratio
43.3%
Financial strength
Net profit 2025
EUR 71K
+50% vs 2024
| Revenue | EUR 1,5M | -8% |
| EBITDA | EUR 121K | +85% |
| Net profit | EUR 71K | +50% |
| Total assets | EUR 826K | +15% |
| Equity | EUR 358K | +25% |
| Employees | — | — |
Legal name
Medans Oy
Y-tunnus number
2078491-4
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
4. joulukuuta 2006
Share capital
EUR 100 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin
Company purpose
Yhtiön toimialana on sairaalatarvikkeiden tuonti, vienti sekä kauppa, dialyysipotilaiden ja siihen läheisesti liittyvien muiden sairauksien hoitoon liittyvien tuotteiden ja palveluiden myynti, yksityinen sairaanhoito ja terveydenhoito, alan tuotteiden tuonti, vienti ja kauppa sekä koulutus ja konsultointi.
Address
Puolikkotie 8
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 749 | 1 957 | 2 188 | 1 676 | 1 545 |
| Staff expenses | −581 | −496 | −460 | −490 | −478 |
| EBITDA | −67 | −13 | 137 | 66 | 121 |
| Depreciation & amort. | −35 | −33 | −31 | −9 | −16 |
| EBIT | −102 | −45 | 106 | 57 | 105 |
| Net financials | −10 | −12 | −6 | −8 | −10 |
| Profit before tax | −112 | −57 | 99 | 49 | 96 |
| Tax | 1 | −0 | −0 | 2 | 25 |
| Net profit | −112 | −57 | 99 | 47 | 71 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 721 | 597 | 624 | 717 | 826 |
| Equity | 198 | 141 | 240 | 287 | 358 |
| Long-term debt | 93 | 32 | 51 | 47 | 173 |
| Short-term debt | 430 | 425 | 333 | 382 | 295 |
| Total debt | 523 | 457 | 384 | 429 | 468 |
EBITDA margin
7.9%
This company
15.8%
Market median
-50% vs market
20212025
Equity ratio
43.3%
This company
38.2%
Market median
+13% vs market
20212025
Return on equity
19.7%
This company
18.4%
Market median
+7% vs market
20212025
Net profit margin
4.6%
This company
8.1%
Market median
-43% vs market
20212025
Asset turnover
1.87×
This company
1.12×
Market median
+67% vs market
20212025
Debt / equity
1.31×
This company
0.62×
Market median
-111% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via PRH / YTJ · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via PRH / YTJ · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via PRH / YTJ · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via PRH / YTJ · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
LT | Audit | 2024 |
PJ Deputy auditor | Deputy auditor | 2024 |
JT Chief Executive Officer | Chief Executive Officer | 2013 |
| Former (2) | ||
KI Audit | Audit | 2010 – 2019 |
TA | Audit | 2019 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2013 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medans Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lauri Tuomas Honkamäki | Audit | 0 companies |
| Perttu Johannes Mettomäki | Deputy auditor | 0 companies |
| Kare Ilari Kotiranta | Audit | 0 companies |
| Teemu Antero Laitinen | Audit | 0 companies |
| Juha Taito Antero Vanhanen | Chief Executive Officer | 0 companies |
| Anna-Kaisa Hertz | Board of Directors | 0 companies |